Suppr超能文献

采用平衡透析变体对药物与血浆蛋白结合进行的研究。

Studies of drug binding to plasma proteins using a variant of equilibrium dialysis.

作者信息

Eriksson Mats A L, Gabrielsson Johan, Nilsson Lars B

机构信息

DMPK and Bioanalytical Chemistry, Local Discovery Research Area CNS and Pain Control, AstraZeneca R and D Södertälje, SE-15185 Södertälje, Sweden.

出版信息

J Pharm Biomed Anal. 2005 Jul 1;38(3):381-9. doi: 10.1016/j.jpba.2005.01.015. Epub 2005 Feb 24.

Abstract

The plasma protein binding of three model compounds was investigated using a variant of equilibrium dialysis, denoted comparative equilibrium dialysis (CED), and the results were compared with those obtained with ultrafiltration (UF). In CED, the buffer that the plasma is dialysed against in traditional equilibrium dialysis is replaced by, for example, plasma from other species. The CED method has the advantage that the unbound concentration (C(u)) does not need to be measured, which can be difficult for drugs with extremely small unbound fractions. Instead, the ratio of the total drug concentration (C(tot)) on either side of the dialysis membrane at equilibrium is a direct measure of the relative binding properties of the two plasma types. For the first model compound, having an unbound fraction (f(u)) of about 0.05% in human plasma, the time to reach equilibrium was too long (> or =40 h) to make the CED technique feasible in practice. For the second model compound, the more weakly bound drug NAD-299 (with an unbound fraction of about 2% in human plasma), the CED equilibration times were considerably shortened (< or =16 h), and the technique was applied to plasma from three different species. Large discrepancies between the CED and UF results were seen, CED always giving rise to much lower C(tot) differences than expected from the UF results. It is suspected that this discrepancy was due to equilibration between the dialysis chambers of all plasma components with a molecular weight less than the cut-off of the membrane. This equilibration causes altered binding properties compared to the initial plasma. When performing ultrafiltration on plasma where drug was added to untreated plasma or added to blank plasma that was equilibrated against plasma from the same or from another species, the change of binding properties was confirmed. To ensure that the results were not specific for NAD-299, a third model compound, tolterodine, was also included. The same trends as for NAD-299 were seen. Because of the long equilibration times for compounds with high protein binding and, in particular, the suspected partial mixture of low molecular weight compounds from the two plasma types and the subsequent change of binding properties, we cannot recommend the CED method as a tool for studying relative protein binding.

摘要

使用平衡透析的一种变体——比较平衡透析(CED)研究了三种模型化合物的血浆蛋白结合情况,并将结果与超滤(UF)所得结果进行了比较。在CED中,传统平衡透析中与血浆进行透析的缓冲液被其他物种的血浆等替代。CED方法的优点是无需测量未结合浓度(C(u)),这对于未结合分数极小的药物可能很难做到。相反,平衡时透析膜两侧总药物浓度(C(tot))的比值可直接衡量两种血浆类型的相对结合特性。对于第一种模型化合物,在人血浆中的未结合分数(f(u))约为0.05%,达到平衡的时间过长(≥40小时),使得CED技术在实际应用中不可行。对于第二种模型化合物,结合较弱的药物NAD - 299(在人血浆中的未结合分数约为2%),CED平衡时间大幅缩短(≤16小时),该技术应用于来自三种不同物种的血浆。CED和UF结果之间存在很大差异,CED产生的C(tot)差异总是比UF结果预期的要低得多。怀疑这种差异是由于分子量小于膜截留值的所有血浆成分在透析室之间达到了平衡。这种平衡导致与初始血浆相比结合特性发生改变。当对添加了药物的未处理血浆或添加了与来自相同或其他物种的血浆平衡过的空白血浆进行超滤时,结合特性的变化得到了证实。为确保结果不是NAD - 299特有的,还纳入了第三种模型化合物托特罗定。观察到与NAD - 299相同的趋势。由于高蛋白结合化合物的平衡时间长,特别是怀疑两种血浆类型中低分子量化合物的部分混合以及随后结合特性的改变,我们不推荐将CED方法作为研究相对蛋白结合的工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验